Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Cerenome reported Q3 2026 CNSide gross billings of $1.55 million on 222 tests billed, with first cash collections expected in Q4 2026. The TCE Test now has 158 million contracted covered lives, tracking toward ~200 million by early 2027, and received a favorable preliminary CMS pricing decision for PLA code 0640U with a January 1, 2027 target effective date. The company targets an annualized gross billing run rate of $10M-$12M in Q4 2026 and will launch the CSF Molecular Profile Test and Breast Cancer Protein Expression Assays in Q4 2026.
Key figures
- Revenue
- $1.55 million
- Guidance
- On track for annualized gross billing run rate of approximately $10M-$12M in Q4 2026; meet or exceed 1,250 total tests annualized in Q4 2026
- Tests billed q3
- 222
- Gross billings q3
- $1.55 million
- Covered lives contracted
- 158 million
- Covered lives target early 2027
- 200 million
- Annualized gross billing run rate target
- $10M-$12M
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.